Estamos realizando la búsqueda. Por favor, espere...
Abstract: Objectives: Adiponectin is an adipokine that plays a relevant role in the development of metabolic syndrome (MetS), a complication that increases the risk of cardiovascular (CV) disease in patients with rheumatoid arthritis (RA). Accordingly, we assessed for the first time the short-term effect of anti-IL-6 receptor tocilizumab (TCZ) administration on adiponectin serum levels in RA patients and explored the potential association of adiponectin levels with MetS features, other CV risk factors and demographic and clinical characteristics of these patients.
Methods: Adiponectin serum levels were evaluated in 50 non-diabetic RA patients, undergoing TCZ treatment, immediately prior to (pre-infusion) and 60 minutes after the end of a TCZ intravenous infusion (post-infusion).
Results: No significant differences in adiponectin levels pre- and post-TCZ infusion were found in RA patients (p=0.69). Patients with obesity exhibited decreased basal levels of adiponectin with respect to those non-obese (p=0.03). Additionally, a negative association of adiponectin basal levels with body mass index, insulin, insulin/glucose index, C-peptide and leptin levels (p<0.01; p=0.02; p=0.03; p=0.03 and p=0.01, respectively), as well as a positive correlation with HDL-cholesterol levels (p<0.001) was seen.
Conclusions: Our results support the claim that low adiponectin may contribute to the development of MetS and, consequently, CV disease in RA. Anti-IL-6 therapy does not seem to exert a short-term effect on adiponectin levels.
Fuente: Clin Exp Rheumatol
. 2022 May;40(5):988-992
Editorial: Clinical and Experimental Rheumatology
Año de publicación: 2022
Nº de páginas: 5
Tipo de publicación: Artículo de Revista
Url de la publicación: https://www.doi.org/10.55563/clinexprheumatol/p8nx80
RICARDO BLANCO ALONSO
FRANCISCO JAVIER LLORCA DIAZ
RIVERA GARCÍA, N.
MIGUEL ANGEL GONZALEZ-GAY MANTECON